Skip to main content
SpringerLink
Log in

Epidemiologie der Hemmkörperhämophilie

  • Conference paper
25. Hämophilie-Symposion Hamburg 1994

  • 22 Accesses

Zusammenfassung

Die Entwicklung von F-VIII-Hemmkörpern stellt eine der schwerwiegendsten Komplikationen in der Behandlung von Hämophilie-A-Patienten dar. Wir verglichen 13 publizierte Studien zur F-VIII-Hemmkörperentwicklung [1, 4 – 9, 13 – 15, 17, 18].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Gill FM (1984) The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 150:19 – 29

    PubMed  CAS  Google Scholar 

  2. Bray GL for the Recombinate Study Group (1992) Clinical experience with recombinant Factor VIII (Recombinate) in previously untreated patients (PUPs) with hemophilia A. Abstract No. 159, XX International Congress of the World Federation of Hemophilia, Athens, Abstractbook, 83

    Google Scholar 

  3. Lusher JM, Arkin S, Abildgaard CF, Mannucci PM, Schwartz RS and the Kogenate Study Group (1992) Recombinant (r) Factor (Kogenate) in previously untreated subjects with Hemophilia A — A three year study. Abstract No. 159, XX International Congress of the World Federation of Hemophilia, Athens, Abstractbook, 94

    Google Scholar 

  4. Rasi V, Ikkala E (1990) Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 76:369 – 371

    Article  PubMed  CAS  Google Scholar 

  5. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS and the Kogenate previously untreated patient Study Group (1993) Recombinant Factor VIII for the treatment of previously untreated patients with Hemophilia A. N Engl J Med 328:453 – 439

    Article  PubMed  CAS  Google Scholar 

  6. De Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D (1994) Incidence of Factor VIII inhibitor development in Hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 71:544–547

    PubMed  Google Scholar 

  7. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L (1993) Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 342:462 – 464

    Article  PubMed  CAS  Google Scholar 

  8. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594 – 98

    Article  PubMed  CAS  Google Scholar 

  9. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao V, Lazerson J and the Hemophilia Study Group (1988) The Natural History of Factor VIII:C Inhibitors in patients with hemophilia A. A national cooperative study. Observations on the initial development of factor VIILC inhibitors. Blood 71:344–348

    PubMed  CAS  Google Scholar 

  10. Lusher JM, Salzman PM and the Monoclate Study Group (1990) Viral safety and inhibitor development associated with factor VIII:C ultra-purified from plasma in haemophiliacs previously unexposed to factor VIII:C concentrate. Semin Haematol 27:1–7

    CAS  Google Scholar 

  11. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher M, Glader B, Aledort L (1992) Inhibitors in factor VIII deficient hemophilia: Comparison of frequency based upon treatment. Abstract No 913 ASH Anaheim Blood 80 (Suppl 1): 231a

    Google Scholar 

  12. Lusher JM, Arkin S, Kreuz W, Mannucci PM, Pearce J and the Kogenate Study Group (1991) Inhibitor (I) development in previously untreated hemophiliacs receiving rF VIII (Kogenate) — is there an increased incidence? Abstract No 217 ASH Denver, Blood 78 (Suppl 1):57 a

    Google Scholar 

  13. Sultan Y and the French Hemophilia Study Group (1992) Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 67:600 – 602

    PubMed  CAS  Google Scholar 

  14. Schwarzinger I, Pabinger I, Korninger C, Haschke F, Kundi M, Niessner H, Lechner K (1987) Incidence of inhibitors in patients with severe and moderate hemophilia A. Treated with factor VIII concentrates. Am J Hematol 24:241 – 245

    Article  PubMed  CAS  Google Scholar 

  15. Bray GL, Liu-Maruya S, Courter S, High K, Gomperts E and the Recombinate Study Group (1992) Experience with recombinant factor VIII (Recombinate) in previously untreated patients (PUPs) with severe hemophilia A. Abstract No 908 ASH Anaheim Blood 80 (Suppl 1): 229 a

    Google Scholar 

  16. Aledort L (1992) Proposal for a standardized protocol for PUP studies to screen for inhibitor formation (SSC on F VIII and IX of the International Society of Thrombosis and Haemostasis) Munich

    Google Scholar 

  17. Ljung R, Petrini P, Lindgren A, Tengborn L, Nilsson I (1992) Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:1550

    Article  PubMed  CAS  Google Scholar 

  18. Lusher JM (1991) Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C. Ann Hematol 63:138 – 141

    Article  PubMed  CAS  Google Scholar 

  19. Bray G, Lee M, Buckwalter C, Lynes M, Courter S, Gomperts E for the Recombinate Study Group (1994) Use of recombinant factor VIII (Recombinate) in previously untreated patients with hemophilia A. Abstract No 107 XXI Int Congr of the World Federation of Hemophilia, Mexico City, Abstract book

    Google Scholar 

  20. Kreuz W, Martinez-Saguer I et al. (1994) Inhibitorinzidenz bei erstbehandelten Hämophilen. Aus: Scharrer I: Erstes deutsches Kogenate Symposium. Klinische Erfahrungen und Sicherheitsaspekte. Pabst, Lengerich, S 126–133

    Google Scholar 

Download references

Authors
  1. W. Kreuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. escuriola-Ettingshausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Martinez-Saguer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Ehrenforth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Lenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Kornhuber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Angiologie, Universitätsklinikum, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Deutschland

    Inge Scharrer

  2. Hämostaseologische Abteilung, Med. Univ.-Klinik Innenstadt, Ziemssenstraße 1a, D-80336, München, Deutschland

    Wolfgang Schramm

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Kreuz, W. et al. (1996). Epidemiologie der Hemmkörperhämophilie. In: Scharrer, I., Schramm, W. (eds) 25. Hämophilie-Symposion Hamburg 1994. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79648-7_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79648-7_33

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-59103-0

  • Online ISBN: 978-3-642-79648-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation